Alpha Tau Medical (NASDAQ:DRTS) Earns “Buy” Rating from HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 287.93% from the company’s previous close.

Separately, Piper Sandler reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Alpha Tau Medical in a research note on Thursday, August 15th.

Alpha Tau Medical Price Performance

Alpha Tau Medical stock opened at $2.32 on Friday. The company has a current ratio of 10.99, a quick ratio of 11.60 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $161.63 million, a P/E ratio of -5.40 and a beta of 0.77. The business has a 50-day moving average of $2.28 and a 200-day moving average of $2.30. Alpha Tau Medical has a 1 year low of $1.75 and a 1 year high of $3.40.

Institutional Trading of Alpha Tau Medical

Hedge funds have recently bought and sold shares of the stock. Aptus Capital Advisors LLC increased its position in shares of Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. raised its stake in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock valued at $56,000 after purchasing an additional 10,000 shares during the period. Caprock Group LLC bought a new stake in shares of Alpha Tau Medical in the second quarter valued at about $59,000. Finally, Levin Capital Strategies L.P. grew its holdings in shares of Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after buying an additional 8,641 shares in the last quarter. 2.65% of the stock is currently owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.